Key result
Selective CCR2 inhibition with GSK1344386B reduced macrophage area in the aortic root by 30% (P<0.05) and decreased USPIO contrast agent uptake on MRI in an atherosclerotic mouse model.
Why the study?
Does GSK1344386B reduce macrophage infiltration into atherosclerotic plaques in ApoE-/- mice?
Does GSK1344386B reduce macrophage infiltration into atherosclerotic plaques in ApoE-/- mice?
Effect estimate: 30% reduction
p-value: p=<0.05
Selective CCR2 inhibition with GSK1344386B decreases macrophage content in atherosclerotic plaques in mice, which can be noninvasively assessed using MRI.
Does not support clinical use of CCR2 inhibition; leaves open translation to human plaque inflammation.
UNLABELLED: Purpose- This study assessed the pharmacological effect of a novel selective C-C chemokine receptor (CCR) 2 antagonist (GSK1344386B) on monocyte/macrophage infiltration into atherosclerotic plaque using magnetic resonance imaging (MRI) in an atherosclerotic mouse model. METHODS AND RESULTS: Apolipoprotein E(-/-) mice expressing human CCR2 were fed a Western diet (vehicle group) or a Western diet plus10 mg/kg per day of GSK1344386B (GSK1344386B group). After the baseline MRI, mice were implanted with osmotic pumps containing angiotensin II, 1000 ng/kg per minute, to accelerate lesion formation. After five weeks of angiotensin II administration, mice received ultrasmall superparamagnetic iron oxide, an MRI contrast agent for the assessment of monocyte/macrophage infiltration to the plaque, and underwent imaging. After imaging, mice were euthanized, and the heart and aorta were harvested for ex vivo MRI and histopathological examination. After 5 weeks of dietary dosing, there were no significant differences between groups in body or liver weight or plasma cholesterol concentrations. An in vivo MRI reflected a decrease in ultrasmall superparamagnetic iron oxide contrast agent uptake in the aortic arch of the GSK1344386B group (P<0.05). An ex vivo MRI of the aortic root also reflected decreased ultrasmall superparamagnetic iron oxide uptake in the GSK1344386B group and was verified by absolute iron analysis (P<0.05). Although there was no difference in aortic root lesion area between groups, there was a 30% reduction in macrophage area observed in the GSK1344386B group (P<0.05). CONCLUSIONS: An MRI was used to noninvasively assess the decreased macrophage content in the atherosclerotic plaque after selective CCR2 inhibition.
No takes yet. Share an insight, caveat, or question.
Olzinski et al. (2009) studied Atherosclerosis. GSK1344386B vs. Vehicle was evaluated on Monocyte/macrophage infiltration into atherosclerotic plaque (30% reduction, p=<0.05). Selective CCR2 inhibition with GSK1344386B reduced macrophage area in the aortic root by 30% (P<0.05) and decreased USPIO contrast agent uptake on MRI in an atherosclerotic mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: